• Publications
  • Influence
Private health expenditure in the Greek health care system: where truth ends and the myth begins.
UNLABELLED Greece today has the most "privatized" health care system among EU countries. Given the country's universal coverage by a public system this may be called "the Greek paradox". TheExpand
Re(I) tricarbonyl complex of 1,10-phenanthroline-5,6-dione: DNA binding, cytotoxicity, anti-inflammatory and anti-coagulant effects towards platelet activating factor.
The complex fac-[Re(CO)3(phendione)Cl] (1) (where phendione=1,10-phenanthroline-5,6-dione) has been synthesized and fully characterized by UV-visible, FTIR, and NMR techniques. The DNA bindingExpand
A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?
In this minireview, we refer to recent results as far as the Platelet Activating Factor (PAF) inhibitors are concerned. At first, results of organic compounds (natural and synthetic ones and specificExpand
The Role of Platelet-Activating Factor in Chronic Inflammation, Immune Activation, and Comorbidities Associated with HIV Infection.
With the advent of highly effective antiretroviral therapy, cardiovascular disease has become an important cause of morbidity and mortality among people with treated HIV-1, but the pathogenesis isExpand
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients
BackgroundPersistent immune activation and inflammation are lying behind HIV-infection even in the setting of ART mediated viral suppression. The purpose of this study is to define the in vivo effectExpand
Effects of Highly Active Antiretroviral Therapy on Platelet Activating Factor Metabolism in Naïve HIV-Infected Patients: II) Study of the Abacavir/Lamivudine/Efavirenz Haart Regimen
Human Immunodeficiency Virus (HIV)-infected patients are at increased risk for cardiovascular diseases partly due to chronic inflammation. Some antiretroviral drugs and Highly Active Anti-RetroviralExpand
Platelet activating factor levels and metabolism in tangier disease: a case study
BackgroundTangier disease (TD) is a phenotypic expression of rare familial syndrome with mutations in the ABCA1 transporter. The risk of coronary artery disease in patients with TD is variable. OnExpand
Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen.
Platelet-activating factor (PAF) is implicated in human immunodeficiency virus (HIV)-related manifestations. Increased PAF synthesis has been recently detected in HIV-infected patients. In thisExpand
1 Re ( I ) tricarbonyl complex of 1 , 10-phenanthroline-5 , 6-dione : DNA binding , cytotoxicity , anti-inflammatory and anticoagulant effects towards Platelet Activating Factor
The complex fac-[Re(CO)3(phendione)Cl] (1) (where phendione=1,10-phenanthroline-5,6dione) has been synthesized and fully characterized by UV-visible, FTIR, and NMR techniques. The DNA bindingExpand
Anti-platelet effects of anti-glaucomatous eye drops: an in vitro study on human platelets
Purpose Altered platelet aggregability has been implicated in the pathogenesis of glaucoma. This study aims to investigate the anti-platelet potential of intraocular pressure lowering drops, with theExpand